- Devonian Health Group has received Health Canada authorization for a 150-patient clinical study evaluating its proprietary Thykamine 0.1% topical formulation to prevent radiodermatitis in women undergoing breast cancer radiotherapy.
- The randomized, double-blind study will compare Thykamine with Glaxal Base cream. Its primary endpoint is time to Grade 2 or higher radiodermatitis, with secondary measures including incidence, pain, patient satisfaction and safety.
- The formulation builds on Thykamine’s preclinical antioxidant and anti-inflammatory findings, expanding the platform into supportive oncology. Its clinical efficacy and safety for preventing radiation-induced skin injury remain to be established.
- Devonian plans to explore a potential medical-device regulatory pathway in Canada, the US and Europe, subject to regulatory confirmation and successful development. The company is preparing for site activation, ethics requirements and clinical supply readiness.
Takeaways:
Devonian’s Thykamine study could expand its antioxidant and anti-inflammatory platform into supportive oncology, targeting radiation-induced skin injury in breast cancer patients. Comparison with Glaxal Base will help establish its clinical value, but efficacy and safety data are needed before differentiation can be confirmed. A potential medical-device pathway could influence commercialization timelines and market access.
Source: CA Newswire
